Evelo Biosciences (EVLO) versus Its Peers Critical Comparison

Share on StockTwits

Evelo Biosciences (NASDAQ: EVLO) is one of 13,326 public companies in the “” industry, but how does it contrast to its peers? We will compare Evelo Biosciences to related businesses based on the strength of its risk, earnings, valuation, institutional ownership, profitability, analyst recommendations and dividends.

Valuation & Earnings

This table compares Evelo Biosciences and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Evelo Biosciences N/A -$56.94 million -3.11
Evelo Biosciences Competitors $7.22 billion $555.84 million 13.68

Evelo Biosciences’ peers have higher revenue and earnings than Evelo Biosciences. Evelo Biosciences is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Evelo Biosciences and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Evelo Biosciences N/A -58.67% -35.26%
Evelo Biosciences Competitors -184.54% 6.33% 1.83%

Institutional and Insider Ownership

85.1% of Evelo Biosciences shares are owned by institutional investors. Comparatively, 55.9% of shares of all “” companies are owned by institutional investors. 13.4% of shares of all “” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Evelo Biosciences and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evelo Biosciences 0 1 4 0 2.80
Evelo Biosciences Competitors 62176 236305 309317 12821 2.44

Evelo Biosciences presently has a consensus target price of $22.75, suggesting a potential upside of 163.31%. As a group, “” companies have a potential upside of 24.00%. Given Evelo Biosciences’ stronger consensus rating and higher probable upside, equities analysts plainly believe Evelo Biosciences is more favorable than its peers.

Summary

Evelo Biosciences peers beat Evelo Biosciences on 7 of the 12 factors compared.

About Evelo Biosciences

Evelo Biosciences, Inc., a biotechnology company, focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815 for patients with psoriasis and atopic dermatitis, rheumatoid arthritis, and ulcerative colitis/crohn's colitis; and EDP1503 for the treatment of colorectal cancer, renal cell carcinoma, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment across multiple tumor types. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for Evelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Weekly Research Analysts’ Ratings Updates for NEWTEK Business Services
Weekly Research Analysts’ Ratings Updates for NEWTEK Business Services
Financial Survey: Trans Energy  and Canadian Natural Resources
Financial Survey: Trans Energy and Canadian Natural Resources
Insolar  Trading Up 12.9% Over Last Week
Insolar Trading Up 12.9% Over Last Week
Insider Selling: Cray Inc.  VP Sells 52,409 Shares of Stock
Insider Selling: Cray Inc. VP Sells 52,409 Shares of Stock
Autohome   Shares Down 6.5%
Autohome Shares Down 6.5%
Invesco Multi-Factor Core Fixed Income ETF  Increases Dividend to $0.07 Per Share
Invesco Multi-Factor Core Fixed Income ETF Increases Dividend to $0.07 Per Share


© 2006-2019 Ticker Report